Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · IEX Real-Time Price · USD
2.550
+0.110 (4.51%)
At close: Jun 21, 2024, 4:00 PM
2.530
-0.020 (-0.78%)
After-hours: Jun 21, 2024, 7:46 PM EDT

Company Description

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer.

It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).

The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia.

In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer.

The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3.

The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Allogene Therapeutics, Inc.
Allogene Therapeutics logo
Country United States
Founded 2017
IPO Date Oct 11, 2018
Industry Biotechnology
Sector Healthcare
Employees 232
CEO Dr. David D. Chang M.D., Ph.D.

Contact Details

Address:
210 East Grand Avenue
South San Francisco, California 94080
United States
Phone (650) 457-2700
Website allogene.com

Stock Details

Ticker Symbol ALLO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001737287
CUSIP Number 019770106
ISIN Number US0197701065
Employer ID 82-3562771
SIC Code 2836

Key Executives

Name Position
Dr. Arie S. Belldegrun F.A.C.S., M.D. Co-Founder and Executive Chairman
Dr. David D. Chang M.D., Ph.D. Co-Founder, President, Chief Executive Officer and Director
Joshua A. Kazam Co-Founder and Director
Geoffrey M. Parker Executive Vice President and Chief Financial Officer
Timothy L. Moore Ph.D. Executive Vice President and Chief Technical Officer
Earl M. Douglas Esq. General Counsel and Compliance Officer
Susan R. Lundeen Chief People Officer
Christine Cassiano Executive Vice President, Chief Corporate Affairs and Brand Strategy Officer
Dr. Zachary J. Roberts M.D., Ph.D. Executive Vice President of Research and Development and Chief Medical Officer
Yinlin Chen Senior Vice President of Finance

Latest SEC Filings

Date Type Title
Jun 18, 2024 144 Filing
Jun 10, 2024 8-K Current Report
May 31, 2024 8-K Current Report
May 29, 2024 144 Filing
May 14, 2024 8-K Current Report
May 14, 2024 424B5 Filing
May 13, 2024 10-Q Quarterly Report
May 13, 2024 8-K Current Report
Apr 25, 2024 EFFECT Notice of Effectiveness
Apr 23, 2024 ARS Filing